Install
Clinical Trials (Phases I–IV)
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Clinical Trials (Phases I–IV)
B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
1+ hour, 22+ min ago (59+ words) B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline: Emerging openPR.com B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight Press release from: ABNewswire Permanent link to this press release: You can edit or delete…...
Cue’s anti-IgE antibody CUE-221 meets Phase II endpoints in chronic urticaria
9+ hour, 23+ min ago (648+ words) AllSci CUE-221 (UB-221), a dual-mechanism anti-IgE monoclonal antibody being developed by Boston-based Cue Biopharma (Nasdaq: CUE), met both its primary and key secondary endpoints in a Phase II study in chronic spontaneous urticaria (CSU), according to topline results released September…...
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
11+ hour, 45+ min ago (90+ words) Cue Biopharma’s potential Xolair challenger passes Phase 2 chronic hives trial Endpoints News Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial Cue Biopharma said Sunday its chron…...
Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
6+ day, 5+ hour ago (758+ words) Sep 15, 2026, 12:46 ET BOSTON, Sept. 15, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced final fifteen-month results from its Phase 1/2 clinical trial evaluating SKY-0515, an investigational oral treatment for Huntington's…...
Definium’s LSD therapy posts second positive Phase III GAD result
6+ day, 6+ hour ago (136+ words) DT120 ODT 100 µg produced a least squares mean HAM-A change of −9.8 versus −4.7 for placebo, a placebo-adjusted difference of −5.1 points (p The 50 µg exploratory arm produced a placebo-adjusted HAM-A reduction of approximately 3.5-3.6 points at Weeks 4 and 12 — roughly 50% and 29% lower than the 100 µg arm,…...
Definium Reports Second Phase III Success in Anxiety Disorder Program
6+ day, 7+ hour ago (353+ words) Year to date, Definium stock has skyrocketed 200.6% against the industry's 2.9% decline. Beyond GAD, Definium is advancing DT120 ODT in major depressive disorder (MDD). DFTX's phase III Emerge study delivered positive top-line results in June 2026, meeting its primary and key secondary endpoints. The…...
H. Lundbeck A/S (OMXCOP:HLUN_A) Completes Randomization in Phase III Dravet Trial
6+ day, 14+ hour ago (128+ words) TradingView H. Lundbeck A/S (OMXCOP:HLUN_A) Completes Randomization in Phase III Dravet Trial H. Lundbeck A/S said the last patient has been randomized in DEEp SEA, a global Phase III trial of bexicaserin for seizures in Dravet syndrome; over 100 participants enrolled,…...
A Single Dose of Pharmaceutical LSD Cut Anxiety Scores Five Points Below Placebo in Phase 3 Trial
6+ day, 23+ hour ago (773+ words) A single dose of a pharmaceutical formulation of LSD cut anxiety scores by about 5 points more than placebo over 12 weeks, according to topline results from the Panorama study released Monday by Definium Therapeutics. Panorama enrolled 245 adults with generalized anxiety disorder…...
Definium’s DT120 ODT Meets Primary Endpoint in Phase 3 GAD Study
6+ day, 15+ hour ago (321+ words) clinicaltrialvanguard.com Definium’s DT120 ODT Meets Primary Endpoint in Phase 3 GAD Study Definium Therapeutics reported positive topline data from its Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder on September 14, 2026, a result that matters because GAD pharmacotherapy has run on…...
VSTM: Advancing RAS/MAPK therapies with pivotal trials and new data to expand cancer treatment options
1+ week, 2+ hour ago (81+ words) TradingView VSTM: Advancing RAS/MAPK therapies with pivotal trials and new data to expand cancer treatment options The session highlighted progress in commercial and clinical programs for RAS/MAPK-driven therapies, including a strong launch for the CO-PACK in ovarian cancer…...